IMR Press / EJGO / Volume 32 / Issue 6 / pii/1630981972070-832954647

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Effect of WT1 antisense mRNA on the induction of apoptosis in ovarian carcinoma SKOV3 cells
Show Less
1 Department of Obstetrics and Gynecology, Beijing General Hospital of Beijing Military Command, Beijing
2 Department of Obstetrics, the First Affiliated Hospital, China Medical University, Shenyang (China)
Eur. J. Gynaecol. Oncol. 2011, 32(6), 651–656;
Published: 10 December 2011

Purpose: To study the effect of WT1 antisense oligodeoxynucleotide (ASODN) transfection on the proliferation and apoptosis of SKOV3 cells. Methods: There were four groups in our study: normal control group, WT1 ASODN group, WT1 SODN group and lipofectamine group. Cell apoptosis was observed by flow cytometry. The effect of WT1 ASODN on cell proliferation was assayed by the MTT method. RT-PCR and Western blot were used to detect the expression level of WT1 mRNA and protein. Results: The growth of the ovarian cancer cell line SKOV3 became significantly slower and its activity was reduced after being transfected by WT1 ASODN, with the inhibition rate of 49.48%. WT1 antisense phosphorothioate oligonucleotides did not only inhibit cell proliferation, arrest cell cycle at G0-G1 checkpoint and induce apoptosis in SKOV3 ovarian carcinoma cells, but also downregulated WT1 mRNA and protein expression, which contributed to the apoptosis (p < 0.05). Conclusion: WT1 antisense phosphorothioate oligonucleotides could both inhibit the proliferation and induce the apoptosis in SKOV3 ovarin carcinoma cell lines. Antisense oligonucleotides of WT1 may potentially help with the gene therapy of ovarian carcinoma.
WT1 gene
Ovarian epithelial carcinoma
Antisense oligonucleotide
SKOV3 cells
Back to top